Carregant...
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps()
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing hematologic malignancies, but how to translate this success to solid malignancies remains elusive. Effective translation of CAR T cells to solid tumors will require an understanding of potential therapeutic barriers,...
Guardat en:
| Publicat a: | Pharmacol Ther |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5035606/ https://ncbi.nlm.nih.gov/pubmed/27373504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2016.06.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|